X-linked Retinoschisis
6
3
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients
Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)
Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)
Clinical Evaluation of Patients With X-linked Retinoschisis